Fri, Apr 19, 2024
Volume 13, Issue 2 (Mar-Apr 2019)
mljgoums 2019, 13(2): 30-33 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Salar Amoli S, Shahin K, Besharat S, Emami Razavi A N, Joshaghani H. Evaluating Association of Tissue Selenium Level and Estrogen Receptor and Progesterone Receptor Expression in Breast Cancer. mljgoums 2019; 13 (2) :30-33
URL: http://mlj.goums.ac.ir/article-1-1100-en.html
URL: http://mlj.goums.ac.ir/article-1-1100-en.html
Sanaz Salar Amoli1 
, Khashayar Shahin2 , Sima Besharat1 , Amir Nader Emami Razavi3 , Hamidreza Joshaghani 4
, Khashayar Shahin2 , Sima Besharat1 , Amir Nader Emami Razavi3 , Hamidreza Joshaghani 4
1- Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran
2- State Key Laboratory Cultivation Base of MOST, Institute of Food Safety and Nutrition, Jiangsu Academy of Agricultural Sciences, Nanjing 210014, PR China and Key Laboratory of Phage Research, International Phage Research Center (IPRC), Jiangsu Academy of Agricultural Sciences, Nanjing, PR China
3- Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran
4- Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran , hr_joshaghani@yahoo.com
2- State Key Laboratory Cultivation Base of MOST, Institute of Food Safety and Nutrition, Jiangsu Academy of Agricultural Sciences, Nanjing 210014, PR China and Key Laboratory of Phage Research, International Phage Research Center (IPRC), Jiangsu Academy of Agricultural Sciences, Nanjing, PR China
3- Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran
4- Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran , hr_joshaghani@yahoo.com
Abstract: (6958 Views)
ABSTRACT
Background and Objectives: Recently, the incidence of breast cancer has increased drastically worldwide. Therefore, the identification of novel diagnostic biomarkers is essential for improving treatment outcomes and prognosis. Estrogen receptor (ER) and progesterone receptor (PR) are routinely available in breast cancer specimens. Semi-quantitative assessment of ER and PR is important for prognosis. Even with the development of genomic tests, hormone receptor status remains the most significant predictive and prognostic biomarker. Selenium is known to protect mammary epithelial cells against oxidative DNA damage and early carcinogenetic events. Since overexpression of ER and PR is common in breast cancers, we aimed to evaluate association of tissue selenium level and ER and PR expression in breast cancer.
Methods: Sixty tissue samples (30 tumors and 30 tumor margins) were collected from patients with breast cancer. Selenium level was measured using graphite furnace atomic absorption spectroscopy and ER/PR expression was evaluated using immunohistochemistry.
Results: About 60% of the samples were positive for ER/PR expression. Mean level of tissue selenium was 209.54 µg/L in tumors and 185.04 µg/L in tumor margins that were ER/PR positive. In addition, mean selenium level was 243.39 µg/L and 168.06 µg/L in ER/PR-negative tumors and tumor margins, respectively. There was no significant association between selenium level and ER/PR expression (P>0.05).
Conclusion: There is no association between tissue Se level and ER/PR expression in breast cancer.
Keywords: Selenium, Estrogen receptor (ER), progesterone receptor (PR), breast cancer.
Background and Objectives: Recently, the incidence of breast cancer has increased drastically worldwide. Therefore, the identification of novel diagnostic biomarkers is essential for improving treatment outcomes and prognosis. Estrogen receptor (ER) and progesterone receptor (PR) are routinely available in breast cancer specimens. Semi-quantitative assessment of ER and PR is important for prognosis. Even with the development of genomic tests, hormone receptor status remains the most significant predictive and prognostic biomarker. Selenium is known to protect mammary epithelial cells against oxidative DNA damage and early carcinogenetic events. Since overexpression of ER and PR is common in breast cancers, we aimed to evaluate association of tissue selenium level and ER and PR expression in breast cancer.
Methods: Sixty tissue samples (30 tumors and 30 tumor margins) were collected from patients with breast cancer. Selenium level was measured using graphite furnace atomic absorption spectroscopy and ER/PR expression was evaluated using immunohistochemistry.
Results: About 60% of the samples were positive for ER/PR expression. Mean level of tissue selenium was 209.54 µg/L in tumors and 185.04 µg/L in tumor margins that were ER/PR positive. In addition, mean selenium level was 243.39 µg/L and 168.06 µg/L in ER/PR-negative tumors and tumor margins, respectively. There was no significant association between selenium level and ER/PR expression (P>0.05).
Conclusion: There is no association between tissue Se level and ER/PR expression in breast cancer.
Keywords: Selenium, Estrogen receptor (ER), progesterone receptor (PR), breast cancer.
Research Article: Original Paper |
Received: 2018/06/30 | Accepted: 2018/06/30 | Published: 2018/06/30 | ePublished: 2018/06/30
Received: 2018/06/30 | Accepted: 2018/06/30 | Published: 2018/06/30 | ePublished: 2018/06/30
References
1. Yao N, Song Z, Wang X, Yang S, Song H. Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients. J Breast Cancer. 2017; 20(2): 160-169. doi: 10.4048/jbc.2017.20.2.160. [DOI:10.4048/jbc.2017.20.2.160]
2. Lubinski J, Marciniak W, Muszynska M, Huzarski T, Gronwald J, Cybulski C, et al. Serum selenium levels predict survival after breast cancer. Breast Cancer Res Treat. 2018; 167(2): 591-8. [DOI:10.1007/s10549-017-4525-9]
3. Parise CA, Caggiano V. Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers. Journal of Cancer Epidemiology. 2014; 2014: 11.
4. Zhang S, Li F, Younes M, Liu H, Chen C, Yao Q. Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium. PLoS One. 2013; 8(5): e63702. doi: 10.1371/journal.pone.0063702. [DOI:10.1371/journal.pone.0063702]
5. Rusolo F, Capone F, Pasquale R, Angiolillo A, Colonna G, Castello G, et al. Comparison of the seleno-transcriptome expression between human non-cancerous mammary epithelial cells and two human breast cancer cell lines. Oncol Lett. 2017; 13(4): 2411-7. doi: 10.3892/ol.2017.5715. [DOI:10.3892/ol.2017.5715]
6. Shamberger RJ, Frost DV. Possible protective effect of selenium against human cancer. Can Med Assoc J. 1969; 100(14): 682.
7. Yang M, Sytkowski AJ. Differential expression and androgen regulation of the human selenium-binding protein gene hSP56 in prostate cancer cells. Cancer Res. 1998; 58(14): 3150-3.
8. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: A randomized controlled trial. JAMA. 1996; 276(24): 1957-63. [DOI:10.1001/jama.1996.03540240035027]
9. Burk RF. Selenium in Nutrition and Healthedited by PF Surai, 2006, 974 pages, hardcover, $149. Nottingham University Press, Nottingham, United Kingdom. The American Journal of Clinical Nutrition. 2007; 86(1): 270. [DOI:10.1093/ajcn/86.1.270]
10. Zeng H, Combs GF, Jr. Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion. J Nutr Biochem. 2008; 19(1): 1-7. [DOI:10.1016/j.jnutbio.2007.02.005]
11. Lee SO, Nadiminty N, Wu XX, Lou W, Dong Y, Ip C, et al. Selenium Disrupts Estrogen Signaling by Altering Estrogen Receptor Expression and Ligand Binding in Human Breast Cancer Cells. Cancer Research. 2005; 65(8): 3487-92. DOI:10.1158/0008-5472.CAN-04-3267. [DOI:10.1158/0008-5472.CAN-04-3267]
12. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. The New England journal of medicine. 2006; 354(3): 270-82. [DOI:10.1056/NEJMra050776]
13. Daniel AR, Hagan CR, Lange CA. Progesterone receptor action: defining a role in breast cancer. Expert Rev Endocrinol Metab. 2011; 6(3): 359-69. doi: 10.1586/eem.11.25. [DOI:10.1586/eem.11.25]
14. Zhang S, Li F, Younes M, Liu H, Chen C, Yao Q. Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium. PLoS One. 2013; 8(5): e63702. doi: 10.1371/journal.pone.0063702. [DOI:10.1371/journal.pone.0063702]
15. Chen YC, Prabhu KS, Das A, Mastro AM. Dietary selenium supplementation modifies breast tumor growth and metastasis. Int J Cancer. 2013; 133(9): 2054-64. doi: 10.1002/ijc.28224. [DOI:10.1002/ijc.28224]
16. Shah YM, Kaul A, Dong Y, Ip C, Rowan BG. Attenuation of Estrogen Receptor α (ERα) Signaling by Selenium in Breast Cancer Cells via Downregulation of ERα Gene Expression. Breast Cancer Research and Treatment. 2005; 92(3): 239-50. [DOI:10.1007/s10549-005-3203-5]
17. Wei XL, He JR, Cen YL, Su Y, Chen LJ, Lin Y, et al. Modified effect of urinary cadmium on breast cancer risk by selenium. Clin Chim Acta. 2015; 438: 80-5. doi: 10.1016/j.cca.2014.08.014. [DOI:10.1016/j.cca.2014.08.014]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.